Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer
E-R modelling in patients with EGFR-mutated NSCLC demonstrated that increased osimertinib exposure was unlikely to increase efficacy but may increase occurrence of certain adverse events. Hence, long-term treatment with doses ≥80 mg was not expected to provide additional benefit.
Authors
- Mikael Sunnåker (ORCID: https://orcid.org/0009-0003-5881-4998)
- Yuri Rukazenkov
- Eline van Maanen
- Helen Tomkinson (ORCID: https://orcid.org/0000-0003-4062-7126)
- Martin Johnson (ORCID: https://orcid.org/0000-0002-4972-7054)
- Yu‐Wei Lin (ORCID: https://orcid.org/0000-0001-7352-0750)
- Karthick Vishwanathan (ORCID: https://orcid.org/0000-0003-4962-5979)
- Henning Schmidt
- Xiangning Huang
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (South Korea) (KR)
- Certara (United States) (US)
- AstraZeneca (Poland) (PL)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1111/bcp.16199
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca